Bizzaro Nicola, Tampoia Marilina
Laboratorio di Patologia Clinica, Ospedale Civile, Via Morgagni, 18, 33028, Tolmezzo, UD, Italy.
Clin Rev Allergy Immunol. 2008 Feb;34(1):16-20. doi: 10.1007/s12016-007-8027-0.
Anticitrullinated protein/peptide antibodies (ACPA) are highly specific for rheumatoid arthritis (RA). They can be found early in the disease course and are associated with more severe joint destruction and disease activity. In the last 4 years, important progress has been made in the detection and identification of ACPA, improving antigenic composition and epitope recognition. Consequently, many ACPA-ELISA kits have been developed by several manufacturers and are now commercially available. However, albeit their widespread use in clinical laboratories, the use of some kits has not been accompanied by a clinical validation nor by a comparative evaluation of their diagnostic accuracy. In addition, full automation of ACPA assays featuring ease of use, rapid response, and high productivity is just beginning to appear on the market and also deserves clinical and analytical validation. This review will consider the most relevant characteristics of the ACPA-ELISA assays and will describe the results of a comparative study performed with all the currently available second- and third-generation commercial methods.
抗瓜氨酸化蛋白/肽抗体（ACPA）对类风湿关节炎（RA）具有高度特异性。它们可在疾病进程早期被发现，且与更严重的关节破坏和疾病活动相关。在过去4年中，ACPA的检测和鉴定取得了重要进展，抗原组成和表位识别得到了改善。因此，多家制造商开发了许多ACPA-ELISA试剂盒，目前已在市场上销售。然而，尽管它们在临床实验室中广泛使用，但一些试剂盒的使用并未伴随临床验证，也未对其诊断准确性进行比较评估。此外，具有易用性、快速响应和高生产率的ACPA检测全自动方法刚刚开始出现在市场上，也值得进行临床和分析验证。本综述将考虑ACPA-ELISA检测的最相关特征，并描述使用所有目前可用的第二代和第三代商业方法进行的比较研究结果。
